[HTML][HTML] First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial
…, A Alexandru, A Vergnenegre, J Raimbourg… - Journal of Thoracic …, 2022 - Elsevier
Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS)
versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater …
versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater …
Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the …
…, D Hochhauser, P Enzinger, J Raimbourg… - JAMA …, 2019 - jamanetwork.com
Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To evaluate …
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To evaluate …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
…, D Moro-Sibilot, JM Michot, J Raimbourg… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
[HTML][HTML] Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
…, JM Wallmark, D Lorente, E Elez, J Raimbourg… - PloS one, 2017 - journals.plos.org
Background Colorectal cancers (CRCs) expressing programmed death ligand 1 (PD-L1)
have poor prognosis. In the multicohort KEYNOTE-028 trial, the anti–PD-1 antibody …
have poor prognosis. In the multicohort KEYNOTE-028 trial, the anti–PD-1 antibody …
[HTML][HTML] Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient …
…, R Sangha, S Ahmed, J Raimbourg… - European journal of …, 2019 - Elsevier
Background In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly
prolonged progression-free survival (co-primary end-point) versus chemotherapy in …
prolonged progression-free survival (co-primary end-point) versus chemotherapy in …
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
…, S Muñiz‐Castrillo, M Roger, J Raimbourg… - Neurology …, 2019 - AAN Enterprises
Objective To report the induction of anti–Ma2 antibody–associated paraneoplastic neurologic
syndrome (Ma2-PNS) in 6 patients after treatment with immune checkpoint inhibitors (ICIs). …
syndrome (Ma2-PNS) in 6 patients after treatment with immune checkpoint inhibitors (ICIs). …
[HTML][HTML] A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced …
…, F Pein, A Blanc-Lapierre, J Raimbourg… - European Journal of …, 2020 - Elsevier
Objective The objectives were to define the maximum tolerated dose (MTD), safety profile
and pharmacokinetics (PKs) of intraperitoneal oxaliplatin delivered by pressurised …
and pharmacokinetics (PKs) of intraperitoneal oxaliplatin delivered by pressurised …
[HTML][HTML] RET-MAP: An international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion
…, M Tagliamento, JR Masip, J Raimbourg… - Journal of Thoracic …, 2023 - Elsevier
Introduction Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare
population is still incomplete. Methods This retrospective multicenter study included patients …
population is still incomplete. Methods This retrospective multicenter study included patients …
[HTML][HTML] Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells
…, G Bougras-Cartron, J Raimbourg… - Cell Death & …, 2020 - nature.com
Anti-PD1 immunotherapy, as a single agent or in combination with standard chemotherapies,
has significantly improved the outcome of many patients with cancers. However, resistance …
has significantly improved the outcome of many patients with cancers. However, resistance …
[HTML][HTML] High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome
…, H Léna, A Teulé, JV Álvarez, J Raimbourg… - Journal of Thoracic …, 2020 - Elsevier
Introduction Actionable somatic molecular alterations are found in 15% to 20% of NSCLC in
Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-…
Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-…